LVTX News and Press, LAVA Therapeutics N.V. From 11/15/23

LAVA Therapeutics N.V. (LVTX) is expected to report $-0.48 for Q3 2023

UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the...

2023-08-22 08:49:15 ET More on LAVA Therapeutics Lava Therapeutics shelves hematology drug over competitive concerns LAVA Therapeutics initiated at buy at Wainwright on Gammabodies to treat cancer Lava Therapeutics begins dosing in phase 1/2a trial of LAVA-1207 to tr...

Significant progress with lead program LAVA-1207 in mCRPC reaching dose level 8 Significant progress with collaborators including selection of lead candidate by Janssen Biotech and IND clearance for SGN-EGFRd2 (LAVA-1223) by Seagen Portfolio reprioritization and extension of cas...

UTRECHT, The Netherlands and PHILADELPHIA , Aug. 14, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody ® platform of bispecific gamma-delta T cell engagers to transf...

2023-06-16 08:33:21 ET Virgin Galactic  ( SPCE ) +42% stock movers today: Virgin Galactic, Coherent and more. VCI Global ( VCIG ) +35% Marks Debut into Artificial Intelligence (“AI”) and Big Data Industries Through Partnership with Fusionex. ...

2023-06-14 11:15:32 ET Lava Therapeutics ( LTRX ) said that it is discontinuing development of its hematology drug candidate LAVA-051 amid competitive concerns and will instead focus on its lead program, LAVA-1207 for the treatment of prostate cancer. Lava said that increased compet...

• LAVA-1207 for the treatment of prostate cancer will continue as the lead program • LAVA-051 Phase 1/2a clinical trial will be discontinued • Associated cost savings and initiatives are expected to extend the cash runway further into 2026 UTRECHT,...

2023-06-08 08:52:43 ET LAVA Therapeutics press release ( NASDAQ: LVTX ): Q1 GAAP EPS of -$0.53. Revenue of $1.22M (+19.6% Y/Y). As of March 31, 2023, LAVA had cash, cash equivalents and investments totaling $125.4 million compared to cash, cash equivalents and investme...

Lead development candidate selected by Janssen Biotech under research collaboration provides a milestone payment to LAVA Strong balance sheet expected to provide cash runway into 2026 UTRECHT, The Netherlands and PHILADELPHIA, June 08, 2023 (GLOBE NEWSWIRE) -- LAVA Thera...